178 related articles for article (PubMed ID: 20691261)
1. Role of IL-6 trans-signaling in CCl₄induced liver damage.
Gewiese-Rabsch J; Drucker C; Malchow S; Scheller J; Rose-John S
Biochim Biophys Acta; 2010 Nov; 1802(11):1054-61. PubMed ID: 20691261
[TBL] [Abstract][Full Text] [Related]
2. IL-6 Trans-signaling Controls Liver Regeneration After Partial Hepatectomy.
Fazel Modares N; Polz R; Haghighi F; Lamertz L; Behnke K; Zhuang Y; Kordes C; Häussinger D; Sorg UR; Pfeffer K; Floss DM; Moll JM; Piekorz RP; Ahmadian MR; Lang PA; Scheller J
Hepatology; 2019 Dec; 70(6):2075-2091. PubMed ID: 31100194
[TBL] [Abstract][Full Text] [Related]
3. IL-6 trans-signaling plays important protective roles in acute liver injury induced by acetaminophen in mice.
Li SQ; Zhu S; Han HM; Lu HJ; Meng HY
J Biochem Mol Toxicol; 2015 Jun; 29(6):288-97. PubMed ID: 25914167
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J
J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364
[TBL] [Abstract][Full Text] [Related]
5. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
6. Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling.
Malchow S; Thaiss W; Jänner N; Waetzig GH; Gewiese-Rabsch J; Garbers C; Yamamoto K; Rose-John S; Scheller J
Biochim Biophys Acta; 2011 Mar; 1812(3):290-301. PubMed ID: 21130161
[TBL] [Abstract][Full Text] [Related]
7. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
[TBL] [Abstract][Full Text] [Related]
8. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.
Rose-John S
Int J Biol Sci; 2012; 8(9):1237-47. PubMed ID: 23136552
[TBL] [Abstract][Full Text] [Related]
9. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.
Rose-John S
Clin Pharmacol Ther; 2017 Oct; 102(4):591-598. PubMed ID: 28675418
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 and its receptor: from bench to bedside.
Scheller J; Rose-John S
Med Microbiol Immunol; 2006 Dec; 195(4):173-83. PubMed ID: 16741736
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 trans-signaling regulates glycogen consumption after D-galactosamine-induced liver damage.
Drucker C; Rabe B; Chalaris A; Schulz E; Scheller J; Rose-John S
J Interferon Cytokine Res; 2009 Nov; 29(11):711-8. PubMed ID: 19642894
[TBL] [Abstract][Full Text] [Related]
12. IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes.
Lee SY; Buhimschi IA; Dulay AT; Ali UA; Zhao G; Abdel-Razeq SS; Bahtiyar MO; Thung SF; Funai EF; Buhimschi CS
J Immunol; 2011 Mar; 186(5):3226-36. PubMed ID: 21282511
[TBL] [Abstract][Full Text] [Related]
13. Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer.
Garbers C; Rose-John S
Methods Mol Biol; 2018; 1725():127-140. PubMed ID: 29322414
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Chalaris A; Schmidt-Arras D; Yamamoto K; Rose-John S
Dig Dis; 2012; 30(5):492-9. PubMed ID: 23108305
[TBL] [Abstract][Full Text] [Related]
15. The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
Rose-John S; Waetzig GH; Scheller J; Grötzinger J; Seegert D
Expert Opin Ther Targets; 2007 May; 11(5):613-24. PubMed ID: 17465721
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities.
Scheller J; Garbers C; Rose-John S
Semin Immunol; 2014 Feb; 26(1):2-12. PubMed ID: 24325804
[TBL] [Abstract][Full Text] [Related]
17. Soluble IL-6R-mediated IL-6 trans-signaling activation contributes to the pathological development of psoriasis.
Xu H; Liu J; Niu M; Song S; Wei L; Chen G; Ding Y; Wang Y; Su Z; Wang H
J Mol Med (Berl); 2021 Jul; 99(7):1009-1020. PubMed ID: 33835216
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis.
Sodenkamp J; Waetzig GH; Scheller J; Seegert D; Grötzinger J; Rose-John S; Ehlers S; Hölscher C
Immunobiology; 2012 Oct; 217(10):996-1004. PubMed ID: 22387074
[TBL] [Abstract][Full Text] [Related]
19. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.
Kallen KJ
Biochim Biophys Acta; 2002 Nov; 1592(3):323-43. PubMed ID: 12421676
[TBL] [Abstract][Full Text] [Related]
20. Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells.
Finotto S; Eigenbrod T; Karwot R; Boross I; Doganci A; Ito H; Nishimoto N; Yoshizaki K; Kishimoto T; Rose-John S; Galle PR; Neurath MF
Int Immunol; 2007 Jun; 19(6):685-93. PubMed ID: 17496315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
